AEterna Zentaris Presents Detailed Positive Phase 2 Data on Ozarelix in Prostate Cancer at SIU Meeting in Cape Town, South Afric
November 13 2006 - 8:30AM
PR Newswire (US)
- First primary endpoint achieved: ozarelix provided testosterone
suppression to castration level at 130 mg every four weeks QUEBEC
CITY, Nov. 13 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX:
AEZ; NASDAQ: AEZS) today presented detailed positive Phase 2
results in hormone-dependent, inoperable prostate cancer for its
luteinizing hormone-releasing hormone (LHRH) antagonist compound,
ozarelix. Results were presented at the Societe Internationale
d'Urologie (SIU) Meeting in Cape Town, South Africa by Professor
Frans M.J. Debruyne from the Department of Urology, University
Medical Center in Nijmegen, The Netherlands, and Chairman of the
European Urology Association. Data showed that the first primary
efficacy endpoint of the study of finding a tolerable dosage
regimen ensuring continuous suppression of testosterone at
castration level (